BioSpace News Archive

Edwards Lifesciences (NYSE: EW ) plans to announce its operating results for the quarter ended December 31, 2022 after the market closes on Tuesday, January 31, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Inversago Pharma Inc. today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its anti-cancer drug Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone treatment.

AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora.

BioStem Technologies Inc. announced that the Center for Medicare Services has established national pricing of VENDAJETM in all Medicare Administrative Contractors regions, effective January 1, 2023.

Kura Oncology, Inc. today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors.

KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.

BioVentrix ® , Inc. today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.

Cerevance announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.

Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”) today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”).